A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1-refractory merkel cell carcinoma.

被引：0
|
作者：
Shalhout, Sophia Z.
Emerick, Kevin S.
Kaufman, Howard E.
Miller, David M.
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA USA
[2] Harvard Med Sch, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA USA
[3] Massachusetts Gen Hosp, Dept Surg, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9521
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma
    Shalhout, Sophia Z.
    Emerick, Kevin S.
    Kaufman, Howard L.
    Silk, Ann W.
    Thakuria, Manisha
    Miller, David M.
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (07) : 299 - 302
  • [2] Real-world assessment of ipilimumab plus nivolumab in anti-PD-L1/PD-1-refractory Merkel Cell Carcinoma
    Shalhout, Sophia Z.
    Emerick, Kevin S.
    Kaufman, Howard L.
    Miller, David M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (10) : 2840 - 2840
  • [3] Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD-1/PD-L1-refractory Merkel cell carcinoma-a case report
    Leven, Anna-Sophia
    Becker, Juergen C.
    Poettgen, Christoph
    Schadendorf, Dirk
    Ugurel, Selma
    Tasdogan, Alpaslan
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (02) : e69 - e71
  • [4] Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy
    Akaike, Tomoko
    Jabbour, Austin J.
    Goff, Peter H.
    Park, Song Y.
    Bhatia, Shailender
    Nghiem, Paul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 5
  • [5] Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
    Alden, Stephanie L.
    Lim, Mir
    Kao, Chester
    Shu, Daniel
    Singal, Amit G.
    Noonan, Anne
    Griffith, Paige
    Baretti, Marina
    Ho, Won Jin
    Kamel, Ihab
    Yarchoan, Mark
    Hsiehchen, David
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (07): : 1312 - 1317
  • [6] Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma
    Teets, Amanda
    Pham, Linda
    Tran, Emma Lan
    Hochmuth, Lana
    Deshmukh, Rahul
    CRITICAL REVIEWS IN IMMUNOLOGY, 2018, 38 (03) : 159 - 206
  • [7] Ipilimumab plus Nivolumab in Avelumab-refractory Merkel Cell Carcinoma - a retrospective multicenter Analysis
    Glutsch, V.
    Kneitz, H.
    Gesierich, A.
    Goebeler, M.
    Posch, C.
    Haferkamp, S.
    Becker, J. C.
    Ugurel, S.
    Schilling, B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 47 - 48
  • [8] Comparison of anti-PD-L1 with anti-PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.
    Li, Shaohua
    Mei, Jie
    Wang, Qiaoxuan
    Zhao, Rongce
    Lu, Lianghe
    Deng, Min
    Lin, Wenping
    Guan, Renguo
    Wen, Yuhua
    Zheng, Lie
    Wei, Wei
    Guo, Rongping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 509 - 509
  • [9] Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
    Glutsch, Valerie
    Kneitz, Hermann
    Gesierich, Anja
    Goebeler, Matthias
    Haferkamp, Sebastian
    Becker, Juergen C.
    Ugurel, Selma
    Schilling, Bastian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (07) : 2087 - 2093
  • [10] Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
    Valerie Glutsch
    Hermann Kneitz
    Anja Gesierich
    Matthias Goebeler
    Sebastian Haferkamp
    Jürgen C. Becker
    Selma Ugurel
    Bastian Schilling
    Cancer Immunology, Immunotherapy, 2021, 70 : 2087 - 2093
12345